Molybdenum
MineralPreclinicalAlso known as: Mo, Mo6+, Mo5+, Mo4+, Molybdate, MoO4, Sodium molybdate, Na2MoO4, Ammonium molybdate, Molybdenum glycinate, Molybdenum chelate, Molybdenum amino acid chelate, Molybdenum citrate, Molybdenum picolinate, Molybdenum aspartate, Molybdenum trioxide, MoO3, Molybdenum disulfide, MoS2, Molybdopterin, Molybdenum cofactor, Moco, Fosdenopterin, Cyclic pyranopterin monophosphate, cPMP, Tetrathiomolybdate, TTM, Ammonium tetrathiomolybdate, ATN-224
Molybdenum is an essential trace mineral that functions as the catalytic metal center of a small but critical set of mammalian enzymes — xanthine oxidase/dehydrogenase, aldehyde oxidase, sulfite oxidase, and mitochondrial amidoxime reducing component (mARC) — all of which carry a shared prosthetic group called the molybdenum cofactor (moco, molybdopterin-Mo complex). Molybdenum is one of the clearest examples of a mineral whose essentiality is not in dispute; loss-of-function mutations in any of the enzymes involved in moco biosynthesis (MOCS1, MOCS2, MOCS3, GPHN) produce molybdenum cofactor deficiency (MoCD), a devastating autosomal recessive metabolic disorder presenting in the neonatal period with intractable seizures, progressive cerebral atrophy, lens dislocation, and death in infancy without treatment.
Overview
At A Glance
Molybdenum's mechanism of action in mammalian physiology centers on its role as the catalytic metal in four molybdenum-containing enzymes, all of which carry a shared molybdopterin cofactor (moco). The cofactor positions molybdenum for two-electron redox chemistry between Mo(IV),…
Mechanism of Action
Molybdenum's mechanism of action in mammalian physiology centers on its role as the catalytic metal in four molybdenum-containing enzymes, all of which carry a shared molybdopterin cofactor (moco). The cofactor positions molybdenum for two-electron redox chemistry between Mo(IV), Mo(V), and Mo(VI) oxidation states, coupled with oxygen atom transfer reactions. Beyond the classical four mammalian moco enzymes, molybdenum has a distinct therapeutic mechanism in copper chelation via tetrathiomolybdate.
Molybdenum cofactor (moco) structure. Moco is an organic-inorganic hybrid: the organic component is molybdopterin (pyranopterin with a dithiolene enedithiolate group), and the inorganic component is a single molybdenum ion coordinated by the two dithiolene sulfurs of the pterin plus two oxygen ligands (oxo, sulfido, or hydroxyl depending on the specific enzyme). In xanthine oxidase and aldehyde oxidase, moco is modified to contain a terminal sulfide (sulfurated moco, generated by molybdenum cofactor sulfurase MOCOS — mutations in MOCOS cause xanthinuria type II). In sulfite oxidase and mARC, moco retains the oxo form. This distinction matters: molybdopterin without appropriate terminal ligand cannot catalyze. Moco is deeply buried in each enzyme's active site and is covalently bound to the protein, making moco biosynthesis essentially irreversible once complete.
Moco biosynthesis pathway. Step 1: MOCS1 (encoded by MOCS1 gene, with alternative splicing producing MOCS1A and MOCS1B) converts guanosine 5'-triphosphate (GTP) to cyclic pyranopterin monophosphate (cPMP) via a radical S-adenosylmethionine (SAM) enzyme MOCS1A and a pterin synthase MOCS1B. MOCS1A contains two [4Fe-4S] clusters, requires SAM, and is oxygen-sensitive. This step is the rate-limiting and first committed step in moco biosynthesis. cPMP is a stable intermediate. Step 2: MOCS2 (with subunits MOCS2A and MOCS2B) converts cPMP to molybdopterin by adding two dithiolene sulfurs from a persulfide on MOCS3, with the pterin ring rearrangement to produce the final pyranopterin molybdopterin structure. Step 3: MOCS3 adenylates molybdopterin to generate MPT-AMP, activating it for molybdenum insertion. Step 4: Gephyrin (GPHN) has dual domains — an N-terminal molybdenum insertion domain and a C-terminal synaptic scaffolding domain. The molybdenum insertion activity incorporates Mo into molybdopterin-AMP, releasing AMP and producing the final moco, which is then released for incorporation into apo-enzymes. Gephyrin's dual role is evolutionarily fascinating — the same protein essential for moco insertion is also essential for GABAergic and glycinergic synapse function via receptor clustering.
Molybdenum cofactor deficiency (MoCD) taxonomy:
- Type A: MOCS1 mutations, loss of cPMP synthesis. Approximately 60% of MoCD cases. Treatable with fosdenopterin (cyclic pyranopterin monophosphate) substrate replacement.
- Type B: MOCS2 mutations, loss of molybdopterin synthesis. Not currently treatable with cPMP (blocked distal to MOCS1).
- Type C: GPHN mutations, loss of molybdenum insertion. Not cPMP-treatable; GPHN mutations also produce synaptic dysfunction via impaired receptor clustering.
- Combined with isolated sulfite oxidase deficiency (SUOX mutations) in phenotypic overlap.
Sulfite oxidase (SUOX). The most clinically important moco enzyme. Catalyzes oxidation of sulfite to sulfate using cytochrome c as the terminal electron acceptor. Sulfite (SO3^2-) is generated from cysteine catabolism via the cysteine → cysteinesulfinate → β-sulfinyl pyruvate pathway, releasing sulfite that must be oxidized to sulfate for safe excretion. When SUOX is deficient (either from SUOX mutations or from moco deficiency), sulfite accumulates and reacts with cystine disulfide bonds to form S-sulfocysteine and S-sulfoglutathione, toxic metabolites that are dramatically elevated in urine and cerebrospinal fluid. S-sulfocysteine has NMDA receptor agonist activity contributing to excitotoxicity; sulfite damages lens proteins causing the characteristic lens dislocation (ectopia lentis) of MoCD. The catastrophic neurodegeneration of MoCD is primarily attributable to SUOX loss.
Xanthine oxidase/dehydrogenase (XDH). Catalyzes hypoxanthine → xanthine → uric acid, the final steps of purine catabolism. Xanthine oxidase is the form that uses molecular oxygen as electron acceptor, producing superoxide and hydrogen peroxide as byproducts (a significant source of oxidative stress). Xanthine dehydrogenase uses NAD+. The two forms are interconvertible post-translationally; XO predominates in tissues and in ischemia-reperfusion contexts where it contributes to oxidative injury. Allopurinol and oxypurinol are xanthine analogs that inhibit XDH; febuxostat is a non-purine structural inhibitor. XDH deficiency (xanthinuria) produces xanthine stones and low serum uric acid. In MoCD, XDH is nonfunctional and patients have very low uric acid (a diagnostic clue).
Aldehyde oxidase (AOX1). Broad-specificity oxidase metabolizing aldehydes to carboxylic acids and oxidizing diverse nitrogen-containing heterocycles. Growing pharmacologic importance: AOX1 metabolizes methotrexate (to 7-hydroxymethotrexate), 6-mercaptopurine, zaleplon, ziprasidone, famciclovir (activation to penciclovir), and many experimental drug candidates. Inter-individual AOX1 activity varies widely, affecting drug clearance for AOX1 substrates. AOX1 is distinct from xanthine oxidase in substrate specificity and regulation though both use molybdenum and FAD in their active site.
Mitochondrial amidoxime reducing component (mARC). Most recently characterized mammalian moco enzyme (Havemeyer 2006). Catalyzes reduction of N-hydroxylated compounds (amidoximes to amidines, hydroxylamines to amines, N-oxides to parent amines). mARC has physiologic roles in reducing endogenous N-hydroxylated intermediates and in drug metabolism (reducing drug metabolites back to active parent compound, sometimes). mARC exists as mARC1 and mARC2 isoforms. Research is active on its roles in fatty acid amide metabolism, nitric oxide homeostasis (reducing nitrite to NO), and drug metabolism.
Tetrathiomolybdate (TTM) mechanism. TTM (MoS4^2-) is an unusual molybdenum compound with four sulfide ligands in place of oxygen. TTM is orally bioavailable and, when absorbed, forms extremely stable Mo-S-Cu complexes that sequester copper — each TTM molecule binds copper irreversibly, rendering the copper bioavailable only for excretion (primarily biliary). TTM binds dietary copper in the gut and serum copper after absorption, and the complex is gradually eliminated. Clinical effects: dramatic reduction in free (non-ceruloplasmin) copper, reduction in total serum copper with time, reduction in copper-dependent enzyme activities (lysyl oxidase, Cu/Zn-SOD, ceruloplasmin ferroxidase, cytochrome c oxidase). Copper is essential (see copper entry), so TTM therapy requires careful dose titration. TTM applications: Wilson disease (de-coppering), investigational for angiogenesis-dependent cancers (solid tumor trials by Redman, Brewer, and colleagues), pulmonary fibrosis (lysyl oxidase dependency), and primary biliary cholangitis (copper accumulation in liver disease).
Pharmacokinetics of supplemental molybdenum. Oral molybdate is efficiently absorbed (40-100%) in proximal small intestine. Absorption competes with sulfate at transporters and is reduced by high copper intake. Absorbed molybdate binds to alpha-2-macroglobulin and erythrocyte proteins; tissue distribution favors liver, kidney, adrenals, and bone. Urinary excretion is dominant (40-80% of intake) with smaller biliary excretion. Serum molybdenum is not routinely measured clinically because of wide inter-individual variation and lack of clear deficiency threshold.
Fosdenopterin (cPMP) pharmacokinetics. The synthetic substrate replacement therapy for MoCD type A. Administered intravenously because cPMP is not orally stable. The drug enters cells via endocytosis or passive diffusion (small molecule, relatively hydrophilic) and substitutes for endogenous cPMP at the MOCS2 step, allowing downstream moco biosynthesis to proceed. Clinical effect: rapid reduction in urinary S-sulfocysteine and xanthine, normalization of sulfite oxidase activity in vivo, prevention (when started early) of further neurologic deterioration.
Serum molybdenum status measurement. Reference range serum molybdenum approximately 0.5-1.5 μg/L; urinary molybdenum 30-100 μg/day at typical intakes. Both have wide variability and are not useful for routine clinical monitoring. Urinary S-sulfocysteine is the primary biomarker for sulfite oxidase deficiency (including MoCD); elevated S-sulfocysteine plus low uric acid is the classic MoCD biochemical signature.
Molybdenum-copper antagonism. In ruminants (cattle, sheep), high dietary molybdenum plus high sulfate produces copper deficiency via formation of insoluble thiomolybdate-copper complexes in the rumen. This is a well-known agricultural problem in molybdenum-rich pastures (molybdenosis). In humans, the same antagonism is the basis of TTM therapy for Wilson disease; at dietary molybdenum levels typical of human intake, copper deficiency is not produced, but high-dose molybdenum supplementation (10+ mg/day) in combination with low dietary copper could theoretically precipitate copper insufficiency.
Overview
Molybdenum is an essential trace mineral that functions as the catalytic metal center of a small but critical set of mammalian enzymes — xanthine oxidase/dehydrogenase, aldehyde oxidase, sulfite oxidase, and mitochondrial amidoxime reducing component (mARC) — all of which carry a shared prosthetic group called the molybdenum cofactor (moco, molybdopterin-Mo complex). Molybdenum is one of the clearest examples of a mineral whose essentiality is not in dispute; loss-of-function mutations in any of the enzymes involved in moco biosynthesis (MOCS1, MOCS2, MOCS3, GPHN) produce molybdenum cofactor deficiency (MoCD), a devastating autosomal recessive metabolic disorder presenting in the neonatal period with intractable seizures, progressive cerebral atrophy, lens dislocation, and death in infancy without treatment. In 2021, the FDA approved fosdenopterin (cyclic pyranopterin monophosphate, cPMP) as the first specific treatment for MoCD type A — the first molybdenum-related pharmacologic approval and one of the more dramatic examples of rescuing a previously uniformly fatal inborn error of metabolism with substrate replacement therapy. The adult body contains only approximately 9 mg of molybdenum, making it one of the trace minerals with the smallest physiologic pool, yet the metabolic consequences of its dysfunction are catastrophic. Peter Jacob Hjelm isolated elemental molybdenum in 1781 from the mineral molybdenite (MoS2); the name derives from the Greek "molybdos" meaning lead, reflecting historic confusion between molybdenum and lead ores. The nutritional essentiality of molybdenum for mammalian biology was established through the 1950s-1960s characterization of xanthine oxidase and aldehyde oxidase as molybdenum-containing enzymes, followed by the elucidation of sulfite oxidase and its critical role in sulfur amino acid catabolism.
The recommended dietary allowance (RDA) for molybdenum is 45 μg/day for adult men and women, with pregnancy and lactation at 50 μg/day. The tolerable upper intake level (UL) is 2,000 μg/day (2 mg/day) for adults, a comparatively wide safety margin (approximately 44-fold above RDA) reflecting molybdenum's low human toxicity at physiologic doses. Children require 17-43 μg/day depending on age. Typical US dietary molybdenum intake ranges 76-109 μg/day, well above the RDA. Molybdenum is widely distributed in foods. Legumes (lima beans, black beans, kidney beans) are particularly rich with 50-150 μg per half-cup, making them the most important dietary source. Whole grains (oats, barley, wheat) provide 30-60 μg per serving. Leafy greens and vegetables contribute variable amounts depending on soil molybdenum content (which varies substantially with geology and agricultural practice). Organ meats (especially beef liver) contain high concentrations. Tap water contributes 2-10 μg per liter. Dietary deficiency of molybdenum in the general population is essentially unknown; deficiency has been reported only in a handful of patients on long-term parenteral nutrition without molybdenum supplementation (Abumrad 1981 AJCN described the index case — a 24-year-old woman on TPN for 18 months who developed intolerance of sulfur amino acids, defective sulfite and purine metabolism, neurologic symptoms including tachycardia, tachypnea, headache, night blindness, coma-like state, and eventual resolution with molybdenum supplementation). This case established the clinical syndrome of acquired molybdenum deficiency and the physiologic requirement.
Molybdenum absorption is relatively efficient. Approximately 40-100% of ingested molybdate is absorbed in the small intestine via passive diffusion and possibly via sulfate transporters (molybdate chemically resembles sulfate and may use the same transporters at low doses). Absorption is reduced by high dietary sulfate intake (competitive inhibition at sulfate transporters) and by copper (forming unabsorbable copper-molybdenum-sulfur complexes in the gut). Absorbed molybdate (MoO4^2-) circulates in plasma bound to alpha-2-macroglobulin and erythrocyte proteins, distributes primarily to liver, kidney, adrenals, and bone, and is excreted predominantly via urine as molybdate (40-80% of intake) with smaller biliary excretion. The biological half-life is hours to days, with little tissue accumulation at physiologic intake. This efficient excretion combined with wide safety margin explains why molybdenum toxicity from dietary supplementation is rare.
Intracellular molybdenum is directed into the molybdopterin synthesis pathway to produce the molybdenum cofactor (moco), a complex organic scaffold that positions molybdenum for enzymatic catalysis. Moco biosynthesis is an ancient, conserved pathway with four sequential steps catalyzed by dedicated enzyme machinery: MOCS1A/B produces cyclic pyranopterin monophosphate (cPMP) from GTP (guanosine triphosphate) via a radical S-adenosylmethionine mechanism — the rate-limiting and first committed step; MOCS2A/B converts cPMP to molybdopterin via the addition of the dithiolene sulfur groups; MOCS3 (adenylates molybdopterin); and gephyrin (GPHN, which has a dual role as a moco-inserting enzyme and as a synaptic scaffolding protein for GABA and glycine receptor clustering) inserts the molybdenum ion into molybdopterin to form the final active moco. Loss of function at any step produces molybdenum cofactor deficiency with the same broad clinical phenotype. MoCD type A (MOCS1 mutations, approximately 60% of cases) is the form treatable with fosdenopterin (synthetic cPMP); MoCD type B (MOCS2) and MoCD type C (GPHN) do not respond to cPMP.
Sulfite oxidase (SUOX) catalyzes the terminal step of cysteine and methionine catabolism, oxidizing sulfite (SO3^2-) to sulfate (SO4^2-) in the liver mitochondrial intermembrane space. Sulfite accumulation in SUOX deficiency or MoCD is particularly neurotoxic — sulfite reacts with cystine disulfide bonds forming S-sulfocysteine, a toxic metabolite that accumulates massively in MoCD patients and in isolated sulfite oxidase deficiency. The severe neurologic phenotype of MoCD (neonatal seizures, cystic encephalopathy, ectopia lentis from sulfite-damaged lens proteins) is primarily attributable to loss of sulfite oxidase function rather than loss of xanthine oxidase or aldehyde oxidase. Isolated sulfite oxidase deficiency (due to SUOX mutations, moco synthesis intact) has nearly identical phenotype to MoCD, confirming the central importance of SUOX in the disease biology.
Xanthine oxidase/dehydrogenase (XDH) catalyzes the final two steps of purine catabolism, converting hypoxanthine to xanthine and xanthine to uric acid. XDH deficiency (xanthinuria type I) produces xanthine accumulation with urolithiasis from xanthine stones. Allopurinol, the classic gout drug, is a xanthine oxidase inhibitor exploiting this biology pharmacologically. Febuxostat is a newer non-purine XDH inhibitor. In MoCD, xanthine oxidase is nonfunctional and patients develop xanthine stones and low uric acid — one of the biochemical signatures of the disease.
Aldehyde oxidase (AOX1) is a broad-specificity oxidase metabolizing diverse aldehydes and azaheterocycles. Aldehyde oxidase is increasingly recognized as a significant drug-metabolizing enzyme in humans, contributing to the oxidation of drugs like methotrexate, famciclovir (to penciclovir), zaleplon, ziprasidone, and carbazeran. Inter-individual variation in AOX1 activity is high, contributing to pharmacokinetic variability for affected drugs. AOX1 activity depends on moco.
Mitochondrial amidoxime reducing component (mARC) — the fourth and most recently characterized mammalian molybdenum enzyme (Havemeyer 2006) — reduces N-hydroxylated compounds back to their amino forms. mARC contributes to the physiologic reduction of drug metabolites (some antimicrobials, anticancer drugs) and endogenous N-hydroxylated intermediates. Biological significance is still being defined.
Beyond metabolism, molybdenum intersects with copper biology through one of the more dramatic therapeutic applications of mineral biology: tetrathiomolybdate (TTM, ATN-224). TTM is an orally bioavailable molybdenum compound that forms stable Mo-S-Cu complexes, irreversibly sequestering copper and dramatically reducing copper bioavailability. TTM is used as copper-chelating therapy in Wilson disease (genetic copper accumulation disorder), with some evidence of superior neurologic outcomes compared to penicillamine in de-coppering treatment phases. TTM has also been investigated as angiogenesis inhibitor in cancer (since copper is required for angiogenesis), and in fibrotic disease and autoimmune disease due to TTM's effects on copper-dependent enzymes (lysyl oxidase, Cu/Zn-SOD). Brewer and colleagues developed the clinical application of TTM in Wilson disease in the 1990s-2000s (Brewer 2006).
BodyHackGuide's take: molybdenum is a true essential mineral with a catastrophic deficiency syndrome at the extremes (MoCD) but near-universal adequacy from ordinary diets. The RDA (45 μg) is easily met by a diet containing legumes, whole grains, or organ meats. Supplementation is not needed for free-living adults with varied diets. Multivitamin content (typically 45-75 μg) is appropriate and harmless. Standalone molybdenum supplements are marketed primarily for candida detoxification and "sulfite sensitivity" support, with minimal evidence base. If supplementation is pursued, 150-500 μg/day of sodium molybdate or glycinate is within safety limits. Therapeutic applications (fosdenopterin for MoCD, tetrathiomolybdate for Wilson disease or cancer research) are specialized and not consumer products. For most users, molybdenum is a background essentiality — present, adequate, not a focus. The biology is elegant (moco as one of the most complex cofactor biosynthesis pathways in nature) but the supplementation implications are modest.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
- Known hypersensitivity to molybdenum (extremely rare).
- TTM specifically in copper-deficient patients without close monitoring.
- Fosdenopterin: reserved for MoCD type A specifically; not effective in MoCD B or C.
Relative contraindications / use with medical supervision:
- Advanced chronic kidney disease (eGFR <30): limit to RDA-level dosing given renal excretion.
- Active gout: avoid supratherapeutic doses (>1 mg/day) which might modestly increase uric acid.
- Pregnancy beyond first trimester at supra-AI doses.
- Active Wilson disease: under hepatology care with specific TTM protocols; self-supplementation contraindicated.
Populations requiring caution:
- Known xanthinuria or xanthine stone formers.
- Chronic copper supplementation users at very high molybdenum doses (potential copper deficiency at 5+ mg/day Mo).
- Sulfite-sensitive individuals who are expecting benefit that may not materialize from molybdenum supplementation.
Clinical warning signs — reassess molybdenum supplementation:
- Unexplained gout attack or hyperuricemia.
- Copper deficiency signs (anemia, neutropenia, neurologic symptoms) in context of chronic high-dose molybdenum.
- Unexplained fatigue or GI symptoms with high-dose use.
Drug interactions:
- Copper supplements: high-dose interaction (thiomolybdate formation); separate or avoid combination.
- Sulfate-containing drugs and high-sulfate diets: reduce molybdenum absorption.
- Allopurinol, febuxostat: no clinically significant interaction at typical supplement doses.
- Drugs metabolized by aldehyde oxidase (methotrexate, zaleplon, ziprasidone, famciclovir): theoretical interactions at physiologic status unlikely clinically significant.
- NSAIDs: no known interaction.
TTM-specific contraindications (therapeutic use):
- Active copper deficiency (baseline).
- Severe bone marrow suppression.
- Pregnancy (fetal copper requirements; use alternative Wilson therapy if needed).
- Known hypersensitivity.
- Close monitoring required for serum copper, ceruloplasmin, CBC, LFTs.
Fosdenopterin contraindications (therapeutic use):
- MoCD types B or C (no benefit; drug does not bypass the block).
- Should be initiated as early as possible (ideally pre-symptomatic or very early symptomatic) for maximum benefit.
Lactation: RDA 50 μg/day. Standard multivitamin content appropriate. Avoid high-dose supplementation.
Driving and operating machinery: no specific concerns; molybdenum has no sedating or impairing effects.
Regulatory status: Dietary supplement category in US (DSHEA 1994). No specific FDA-approved disease indications for consumer molybdenum. Fosdenopterin approved for MoCD type A (2021). TTM not FDA-approved (used under specialty protocols for Wilson disease). ALXN1840 FDA approval declined 2022; development ongoing.
Laboratory interferences: none of clinical significance.
Environmental exposure: drinking water molybdenum is generally not a health concern; occupational exposure is managed under OSHA standards.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for Molybdenum.
Related Compounds
View AllBoron
MineralPreclinicalBoron is an ultra-trace element whose nutritional status in humans sits in a distinctive regulatory gray zone: the Institute of Medicine (US) has not established a recommended dietary allowance (RDA) or estimated average requirement (EAR) for boron because the evidence for essentiality in humans does not meet the strict criteria applied to calcium, iron, or zinc, yet the IOM, the European Food Safety Authority (EFSA), and the World Health Organization (WHO) all set tolerable upper intake levels (ULs) — implicitly acknowledging that boron has biological activity and dose-response safety concerns.
Calcium
MineralPreclinicalCalcium is the most abundant mineral in the human body — roughly 1,000 to 1,500 grams in a 70 kg adult, with 99% sequestered in the skeleton and teeth as crystalline hydroxyapatite [Ca10(PO4)6(OH)2], and the remaining 1% distributed across extracellular fluid, intracellular cytoplasm, mitochondria, and the endoplasmic/sarcoplasmic reticulum.
Chromium
MineralPreclinicalChromium is a transition metal that occupies one of the more peculiar positions in human nutrition: long marketed as essential for carbohydrate metabolism and insulin sensitization, the evidence for chromium essentiality has progressively softened over the past two decades, and both the European Food Safety Authority (EFSA 2014) and multiple independent reviews have concluded that chromium III is not definitively essential for humans.
Copper
MineralPreclinicalCopper is an essential trace mineral that most adults get in adequate amounts from a varied omnivorous diet — but that routinely drops into functional insufficiency when people take long-term high-dose zinc supplements, consume highly processed diets, undergo bariatric surgery, or use copper-chelating therapies.
Iodine
MineralPreclinicalIodine is a halogen trace mineral and an obligate substrate for thyroid hormone synthesis — the single biochemical fact that dominates all clinical thinking about iodine.
Iron
MineralPreclinicalIron is a trace mineral with a biochemistry dominated by a single chemical property — the reversible one-electron redox between Fe²⁺ (ferrous) and Fe³⁺ (ferric) — that makes it indispensable for oxygen transport, electron transfer, and hundreds of enzymatic reactions, and simultaneously dangerous when unchaperoned in cells.
View Full Dosage Guide →
Protocols, calculator & safety for Molybdenum
Research Score
76143 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
What does molybdenum do in the body?
Molybdenum is an essential trace mineral that functions as the catalytic metal center for four specific mammalian enzymes, all sharing a complex organic cofactor called the molybdenum cofactor (moco, molybdopterin-Mo complex). The four enzymes are: (1) xanthine oxidase/dehydrogenase (XDH), which catalyzes the final steps of purine catabolism, converting hypoxanthine to xanthine and xanthine to uric acid — the target of allopurinol and febuxostat in gout treatment; (2) sulfite oxidase (SUOX), which catalyzes the terminal step of cysteine and methionine catabolism, oxidizing toxic sulfite to sulfate for excretion — critical for preventing sulfite accumulation that damages lens proteins and produces S-sulfocysteine neurotoxin; (3) aldehyde oxidase (AOX1), a broad-specificity oxidase metabolizing diverse aldehydes and increasingly recognized as a major drug-metabolizing enzyme for methotrexate, zaleplon, ziprasidone, famciclovir, and others; and (4) mitochondrial amidoxime reducing component (mARC), the most recently characterized moco enzyme, which reduces N-hydroxylated compounds and plays roles in drug metabolism and nitric oxide homeostasis. Beyond these enzymatic roles, molybdenum in the form of tetrathiomolybdate (TTM) is used therapeutically to chelate copper in Wilson disease, exploiting the stable Mo-S-Cu complex that sequesters copper for excretion. The body contains only about 9 mg total molybdenum distributed mainly in liver, kidney, adrenals, and bone, and despite this small pool, severe molybdenum cofactor deficiency (MoCD) is among the most catastrophic inborn errors of metabolism with uniformly fatal neonatal presentation without treatment. PMID 6784385 (Abumrad 1981) established human molybdenum essentiality; PMID 19956895 reviews the four mammalian moco enzymes.
Is molybdenum essential and do I need to supplement it?
Molybdenum is definitively essential for human life — far more clearly than borderline-essential minerals like chromium. The catastrophic phenotype of molybdenum cofactor deficiency (uniformly fatal neonatal encephalopathy without treatment) leaves no ambiguity about essentiality. However, the practical question of whether to supplement is different: the US RDA is 45 μg/day, typical US adult intake is 76-109 μg/day, and dietary deficiency in free-living adults has never been documented. The only reported acquired deficiency in adults was the Abumrad 1981 case of a woman on long-term parenteral nutrition without molybdenum, who developed sulfur amino acid intolerance and neurologic symptoms reversed by molybdenum repletion. For anyone eating ordinary food — particularly legumes (lima beans, black beans, kidney beans), whole grains (oats, barley, wheat), organ meats, and vegetables — molybdenum intake easily exceeds the RDA. A multivitamin with 45-75 μg molybdenum is appropriate and sufficient. Standalone molybdenum supplementation is not needed for general health. Marketing claims for candida treatment, heavy metal detoxification, or sulfite support are not backed by convincing evidence. If considering molybdenum for sulfite sensitivity specifically (a somewhat more plausible rationale), a trial of 150-500 μg/day for 1-3 months with symptom reassessment is reasonable, but expectations should be modest. The bottom line: molybdenum is essential but near-universally adequate from diet, and supplementation is low-priority for most users. PMID 11110839 (Institute of Medicine DRI report) established the current RDA/UL framework.
What is molybdenum cofactor deficiency (MoCD)?
Molybdenum cofactor deficiency is a rare autosomal recessive disorder caused by mutations in enzymes of molybdenum cofactor biosynthesis, leading to loss of function of all four mammalian molybdenum-dependent enzymes. Three genetic subtypes are recognized: type A (MOCS1 mutations, approximately 60% of cases) — loss of cyclic pyranopterin monophosphate (cPMP) synthesis; type B (MOCS2 mutations) — loss of molybdopterin synthesis; type C (GPHN mutations) — loss of molybdenum insertion into molybdopterin, and GPHN mutations also disrupt synaptic GABA/glycine receptor clustering. The clinical phenotype is severe and uniform across subtypes: neonatal onset within days to weeks of birth, intractable seizures refractory to standard anticonvulsants, progressive cystic encephalomalacia on brain imaging, microcephaly, ectopia lentis (lens dislocation from sulfite-damaged lens proteins), feeding difficulties, hypotonia, and death typically before age 2-3 years without specific treatment. The biochemical signature is diagnostic: markedly elevated urinary S-sulfocysteine (from sulfite damage to cystine), elevated urinary xanthine and hypoxanthine, very low uric acid (because XDH is non-functional), and elevated urinary sulfite (detectable on dipstick at bedside). In 2021, the FDA approved fosdenopterin (synthetic cPMP, brand name Nulibry) as the first specific therapy, usable only in MoCD type A. Early initiation (pre-symptomatic or in early symptomatic period, ideally days to weeks of life) produces dramatic biochemical improvement and substantial neurologic protection; late initiation produces biochemical but limited neurologic response. MoCD types B and C remain without specific therapy. Newborn screening for MoCD is expanding in US states and European countries. PMID 26231459 (Schwahn 2015 Lancet) reported multi-patient fosdenopterin outcomes; PMID 20956417 (Veldman 2010 Pediatrics) reported the index successful clinical treatment.
What is tetrathiomolybdate (TTM) and how is it used?
Tetrathiomolybdate (TTM, MoS4^2-) is an unusual molybdenum compound with four sulfide ligands replacing the typical oxygen coordination — giving it a strong affinity for copper. Orally administered TTM forms stable Mo-S-Cu complexes that sequester copper and render it bioavailable only for excretion. This mechanism makes TTM a potent copper chelator with several therapeutic applications. Wilson disease: newly diagnosed Wilson disease patients, particularly those with neurologic presentation, benefit from rapid de-coppering. TTM (120-300 mg/day divided between mealtime and between-meal doses to bind both dietary and systemic copper) for an initial 8-week course reduces copper load and has been shown to produce less early neurologic worsening than penicillamine (a known penicillamine complication attributed to mobilization of copper with delayed excretion). Maintenance is then typically zinc acetate (which blocks copper absorption). ALXN1840 (bis-choline tetrathiomolybdate) is a phase 3-tested developmental oral TTM formulation; FDA approval was declined in 2022 and development status is being reassessed. Cancer: copper is required for angiogenesis (via lysyl oxidase maturation and VEGF signaling). TTM has been investigated in phase 1/2 trials for metastatic cancer with variable signals in head-and-neck cancer, breast cancer, and glioblastoma, but without definitive efficacy; current development is research-phase. Pulmonary fibrosis: lysyl oxidase is copper-dependent, and TTM has been investigated for idiopathic pulmonary fibrosis; signals are modest. TTM is not a consumer supplement — it is a specialty therapeutic used under hepatology or oncology care. PMID 16908725 (Brewer 2006) describes the Wilson disease protocol; PMID 10656441 (Brewer 2000) reported initial cancer phase 2 findings.
Can molybdenum help with sulfite sensitivity?
The theoretical rationale is plausible but the clinical evidence is thin. Molybdenum-dependent sulfite oxidase (SUOX) catalyzes the conversion of toxic sulfite (SO3^2-) to safe sulfate (SO4^2-) in the liver. If SUOX function is rate-limiting, additional molybdenum might enhance sulfite clearance. Molybdenum supplementation is therefore marketed for 'sulfite sensitivity' — reactions to wines, dried fruits, processed foods, and shrimp preserved with sulfite. The clinical reality is more complicated. Most sulfite sensitivity is either IgE-mediated allergic (anaphylaxis, urticaria — independent of SUOX activity) or non-immunologic (asthma-like reactions, headaches — mechanism unclear, not necessarily SUOX-related). True SUOX enzyme deficiency is a severe pediatric metabolic disorder (isolated sulfite oxidase deficiency, from SUOX mutations) with catastrophic neurologic phenotype — not adult-onset 'sensitivity.' A subset of people with mild, non-severe sulfite reactions may have subclinical reductions in SUOX activity where molybdenum adequacy could theoretically matter, but this hypothesis has not been well-tested in controlled trials. Published evidence consists of case reports and small uncontrolled studies. For a person with reported sulfite sensitivity, the evidence-based workup is (1) allergy specialist evaluation for IgE-mediated reactions, (2) identification of specific sulfite-containing foods that trigger symptoms, (3) avoidance strategy. A trial of molybdenum supplementation at 150-500 μg/day for 1-3 months is reasonable as a low-cost, low-risk experiment, but expectations should be modest and discontinuation indicated if no meaningful symptom improvement. Do not take high-dose molybdenum (1-5 mg/day) as marketed by some aggressive supplement brands.
Is molybdenum linked to copper deficiency?
Yes, at high molybdenum intakes combined with low copper intakes, there is a well-established antagonism. Molybdate and sulfide in the gut form thiomolybdate complexes with copper that are poorly absorbed, reducing dietary copper bioavailability. At even higher molybdenum doses, systemic thiomolybdate formation can deplete tissue copper — the basis of tetrathiomolybdate (TTM) as a therapeutic copper chelator in Wilson disease. In ruminants (cattle, sheep) grazing on high-molybdenum pastures, this interaction produces 'molybdenosis' — clinical copper deficiency causing growth retardation, anemia, bone abnormalities, and neurologic signs. For humans, dietary molybdenum intake from ordinary foods (76-109 μg/day) is far below the threshold for copper antagonism, and multivitamin molybdenum content (45-75 μg) is harmless. However, chronic high-dose molybdenum supplementation (1-5 mg/day) combined with low-copper diets could theoretically produce copper insufficiency. This is another reason we do not recommend high-dose molybdenum supplementation for free-living adults. If you are supplementing copper for any reason (copper deficiency diagnosis, IUD-related concerns, specific nutritional goals) and also supplementing molybdenum, use only multivitamin-level molybdenum doses (45-150 μg/day) to avoid antagonism. Conversely, if Wilson disease is being treated with TTM, copper-containing supplements are contraindicated (they would antagonize the therapy). The clinical signal in most users is low, but the interaction is real at the extremes.
How does molybdenum compare to other trace minerals in importance?
Among the essential trace minerals, molybdenum is unambiguously essential (catastrophic pediatric deficiency phenotype), near-universally adequate in diet (deficiency essentially unknown in free-living populations), and low-priority for supplementation (no demonstrated benefit above RDA for ordinary users). This positions it differently from other trace minerals: Iron — essential, commonly deficient in menstruating women and vegetarians, supplementation often indicated. Iodine — essential, deficiency regionally common, supplementation via salt iodization widely implemented. Zinc — essential, deficiency common in elderly and GI disease, supplementation often beneficial. Copper — essential, deficiency less common but possible, supplementation rarely indicated. Selenium — essential, deficiency regionally common (soil-dependent), supplementation sometimes indicated. Chromium — essentiality debated (EFSA 2014 removed from essential list), deficiency not demonstrable, supplementation weak evidence. Manganese — essential, deficiency rare, supplementation not recommended. Molybdenum — essential, deficiency essentially unknown, supplementation not needed for ordinary users. The practical 'stack' of trace mineral priorities for most users: iron if iron-deficient (or menstruating and borderline), iodine if in deficient region or on dairy-free diet, zinc if GI disease or vegan, selenium if in low-soil region, vitamin-adequate D and multivitamin for baseline coverage. Molybdenum, chromium, and manganese all fall into the background category where multivitamin content is sufficient and standalone supplementation is rarely meaningful. This hierarchy reflects the contrast between essential (definitely required) and practical-priority (actually needing supplementation in modern diets).
What is fosdenopterin and why is it significant?
Fosdenopterin is a synthetic cyclic pyranopterin monophosphate (cPMP), the first committed intermediate in molybdenum cofactor (moco) biosynthesis. In molybdenum cofactor deficiency type A (the most common subtype, from MOCS1 mutations), the MOCS1 enzyme cannot produce cPMP, blocking all downstream moco synthesis and causing catastrophic multi-enzyme deficiency. Fosdenopterin, administered IV daily, substitutes for endogenous cPMP at the next biosynthetic step (MOCS2, which is intact in type A patients), allowing downstream moco synthesis to proceed and restoring sulfite oxidase, xanthine oxidase, aldehyde oxidase, and mARC function. This is one of the most elegant examples of substrate replacement therapy in all of metabolic medicine — providing a small molecule that bypasses a single defective biosynthetic step to reconstitute an entire multi-enzyme system. Clinical impact: untreated MoCD-A is uniformly fatal in infancy; early initiation of fosdenopterin (ideally pre-symptomatic or within days-weeks of first symptoms) dramatically improves survival and neurologic outcomes. Late initiation produces biochemical improvement but limited neurologic reversal. The drug does NOT work in MoCD-B or MoCD-C (MOCS2 or GPHN mutations) because the block is downstream of cPMP. FDA approval was granted in February 2021 under the brand name Nulibry (Origin BioSciences, subsequently Sentynl Therapeutics). The significance extends beyond MoCD-A itself: fosdenopterin is one of the first-generation substrate replacement therapies approved for ultra-rare metabolic disorders (approximately 100 cases of MoCD-A worldwide), establishing a regulatory and clinical precedent for treating similar metabolic bottlenecks, and demonstrating that substrate replacement can reconstitute multi-enzyme cofactor-dependent systems. PMID 26231459 (Schwahn 2015 Lancet) reports the pivotal trial outcomes; PMID 20956417 (Veldman 2010 Pediatrics) reported the first clinical success. Newborn screening expansion for MoCD-A is a critical complement to fosdenopterin availability.
Is molybdenum safe during pregnancy and in children?
At RDA-level intake, molybdenum is safe during pregnancy and for children. The pregnancy and lactation RDA is 50 μg/day (only slightly above the adult 45 μg/day). Standard prenatal multivitamins contain 45-75 μg molybdenum, which is appropriate. Dietary intake from legumes, whole grains, and organ meats easily meets this requirement. The tolerable upper intake level for pregnant women is 1,700 μg/day (16-18 years) or 2,000 μg/day (>18 years), providing a wide safety margin. High-dose molybdenum supplementation (>1 mg/day) is not recommended in pregnancy without specific medical indication — animal studies at very high doses have shown some developmental abnormalities, though human data at modest doses is reassuring. For children, the RDA is age-adjusted: 17 μg (1-3 years), 22 μg (4-8 years), 34 μg (9-13 years), 43 μg (14-18 years). Pediatric multivitamins contain appropriate molybdenum. Standalone pediatric molybdenum is not indicated except in specific medical conditions (molybdenum cofactor deficiency with fosdenopterin, long-term parenteral nutrition). Important pediatric context: severe infantile seizures with encephalopathy, ectopia lentis, or unexplained metabolic abnormalities should prompt evaluation for MoCD — this is not a 'molybdenum deficiency' in the nutritional sense but an inborn error requiring specialist genetic and metabolic care. For neonatal screening, some US states and European countries have added MoCD to newborn panels, facilitating early fosdenopterin initiation for treatable cases. General pediatric nutrition: dietary molybdenum from beans, grains, leafy greens, and organ meats is adequate for children's needs.
Should I worry about molybdenum exposure from occupational or environmental sources?
For most people, no. Molybdenum has a wide safety margin and low acute and chronic toxicity relative to other metals. OSHA permissible exposure limits are 5 mg/m3 for soluble molybdenum and 15 mg/m3 for total molybdenum dust — substantially higher than limits for more toxic metals (mercury, lead, cadmium, chromium VI). Occupational exposure of concern occurs in molybdenum mining (Colorado Rocky Mountains, Chile, China), molybdenum trioxide production, ferromolybdenum and stainless steel production, tungsten-carbide tool manufacturing, and some specialty ceramics. Workers in these industries should follow standard industrial hygiene practices (ventilation, PPE, respirators in dust-prone tasks). Long-term high-dose occupational exposure has been associated with pneumoconiosis in some worker cohorts and mild gout-like symptoms from increased uric acid production. Environmental exposure from drinking water or soil is generally low-concern: molybdenum-rich geology (parts of Armenia, Colorado, Scandinavia) can produce elevated dietary intake (5-10 mg/day in some historical reports) associated with gout-like symptoms, but this is a rare agricultural phenomenon, not a general environmental concern. US drinking water typically contains 1-10 μg/L molybdenum, far below any health-based threshold. EPA has no federal MCL specifically for molybdenum (the health reference level for drinking water is 40 μg/L but this is not enforced as a primary standard). For consumer supplementation, typical doses (45-500 μg/day) are orders of magnitude below the 2,000 μg/day UL and do not constitute meaningful exposure concern. If specific local geology raises concerns, local water quality reports and state health departments can provide guidance; for most users, molybdenum from diet and supplementation is a non-issue from a toxicity standpoint.
Research Tools
Related Compounds
View AllBoron
MineralPreclinicalBoron is an ultra-trace element whose nutritional status in humans sits in a distinctive regulatory gray zone: the Institute of Medicine (US) has not established a recommended dietary allowance (RDA) or estimated average requirement (EAR) for boron because the evidence for essentiality in humans does not meet the strict criteria applied to calcium, iron, or zinc, yet the IOM, the European Food Safety Authority (EFSA), and the World Health Organization (WHO) all set tolerable upper intake levels (ULs) — implicitly acknowledging that boron has biological activity and dose-response safety concerns.
Calcium
MineralPreclinicalCalcium is the most abundant mineral in the human body — roughly 1,000 to 1,500 grams in a 70 kg adult, with 99% sequestered in the skeleton and teeth as crystalline hydroxyapatite [Ca10(PO4)6(OH)2], and the remaining 1% distributed across extracellular fluid, intracellular cytoplasm, mitochondria, and the endoplasmic/sarcoplasmic reticulum.
Chromium
MineralPreclinicalChromium is a transition metal that occupies one of the more peculiar positions in human nutrition: long marketed as essential for carbohydrate metabolism and insulin sensitization, the evidence for chromium essentiality has progressively softened over the past two decades, and both the European Food Safety Authority (EFSA 2014) and multiple independent reviews have concluded that chromium III is not definitively essential for humans.
Copper
MineralPreclinicalCopper is an essential trace mineral that most adults get in adequate amounts from a varied omnivorous diet — but that routinely drops into functional insufficiency when people take long-term high-dose zinc supplements, consume highly processed diets, undergo bariatric surgery, or use copper-chelating therapies.
Iodine
MineralPreclinicalIodine is a halogen trace mineral and an obligate substrate for thyroid hormone synthesis — the single biochemical fact that dominates all clinical thinking about iodine.
Iron
MineralPreclinicalIron is a trace mineral with a biochemistry dominated by a single chemical property — the reversible one-electron redox between Fe²⁺ (ferrous) and Fe³⁺ (ferric) — that makes it indispensable for oxygen transport, electron transfer, and hundreds of enzymatic reactions, and simultaneously dangerous when unchaperoned in cells.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
